Connect with us

Technology

RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders’ Equity Deficiency

Published

2 years ago

on

The Notification Letter has no immediate effect on the Company’s listing on the Nasdaq Capital Market at this time, nor are the Company’s business operations affected by receipt of the Notification Letter

TEL AVIV, Israel and RALEIGH, N.C., April 17, 2025 /PRNewswire/ — RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that the Company received a written notification (the “Notification Letter”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) dated April 15, 2025, notifying the Company that it is no longer in compliance with Nasdaq Listing Rule 5550(b)(1) (the “Rule”).

The Rule requires companies listed on the Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. However, based on the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2024, filed on April 10, 2025, the Company reported a stockholders’ deficit of $4,683,000, and does not meet the alternatives of market value of listed securities or net income from continuing operations, and is thus non-compliant with the Rule.

The Notification Letter has no immediate effect on the Company’s listing on the Nasdaq Capital Market at this time, nor are the Company’s business operations affected by receipt of the Notification Letter. In accordance with the Nasdaq Listing Rules, the Company has 45 calendar days, or until May 30, 2025, to submit a plan to regain compliance. If the plan is accepted, Nasdaq can grant an extension of up to 180 calendar days from receipt of the Notification Letter to evidence compliance.

The Company is looking into various options available to regain compliance and maintain its continued listing on the Nasdaq Capital Market. The Company intends to submit the compliance plan as soon as practicable. There can be no assurance that the Company’s plan will be accepted or the Company will be able to regain compliance with the Rule.

About RedHill Biopharma 

RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on U.S. development and commercialization of drugs for gastrointestinal diseases, infectious diseases and oncology. RedHill promotes the FDA-approved gastrointestinal drug Talicia, for the treatment of Helicobacter pylori (H. pylori) infection in adults[1], with submission planned for marketing authorization in other territories. RedHill’s key clinical late-stage development programs include: (i) opaganib (ABC294640), a first-in-class, orally administered sphingosine kinase-2 (SPHK2) selective inhibitor with anticancer, anti-inflammatory and antiviral activity, targeting multiple indications with U.S. Government and academic collaborations for development for radiation and chemical exposure indications such as Gastrointestinal-Acute Radiation Syndrome (GI-ARS), a Phase 2 study in prostate cancer in combination with Bayer’s darolutamide and a Phase 2/3 program for hospitalized COVID-19 patients; (ii) RHB-204, an all-in-one, fixed-dose, orally administered, combination antibiotic therapy with a planned Phase 2 study for Crohn’s disease and Phase 3-stage for pulmonary nontuberculous mycobacterial (NTM) disease; (iii) RHB-104, with positive results from a first Phase 3 study for Crohn’s disease; (iv) RHB-107 (upamostat), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness, is in late-stage development as a treatment for non-hospitalized symptomatic COVID-19 and is also targeting multiple other cancer and inflammatory gastrointestinal diseases; and (v) RHB-102, with potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting, positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D. RHB-102 is partnered with Hyloris Pharma (EBR: HYL) for worldwide development and commercialization outside North America.

More information about the Company is available at www.redhillbio.com / X.com/RedHillBio. 

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: market and other conditions; the Company’s ability to regain and maintain compliance with the Nasdaq Capital Market’s listing requirements; the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk of current uncertainty regarding U.S. government research and development funding and that the U.S. government is under no obligation to continue to support development of our products and can cease such support at any time; the risk that acceptance onto the RNCP Product Development Pipeline or other governmental and non-governmental development programs will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company’s proposed development plans for its programs; the risk that the Company’s development programs and studies may not be successful and, even if successful, such studies and results may not be sufficient for regulatory applications, including emergency use or marketing applications, and that additional studies may be required; the risk of market and other conditions and that the Company will not successfully commercialize its products; as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company’s research, manufacturing, pre-clinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its pre-clinical studies or clinical trials or the development of any necessary commercial companion diagnostics; (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company’s therapeutic candidates and Talicia®; (v) the Company’s ability to successfully commercialize and promote Talicia®; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) the Company’s ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company’s therapeutic candidates and the results obtained with its therapeutic candidates in research, pre-clinical studies or clinical trials; (ix) the implementation of the Company’s business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company’s expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under the Company’s Expanded Access Program; (xiv) competition from other companies and technologies within the Company’s industry; and (xv) the hiring and employment commencement date of executive managers. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 20-F filed with the SEC on April 10, 2025. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.

Company contact:

Adi Frish
Chief Corporate and Business Development Officer
RedHill Biopharma
+972-54-6543-112
adi@redhillbio.com

Category: Corporate

[1] Talicia® (omeprazole magnesium, amoxicillin and rifabutin) is indicated for the treatment of H. pylori infection in adults. For full prescribing information see: www.Talicia.com.

Logo – https://mma.prnewswire.com/media/1334141/RedHill_Biopharma_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/redhill-biopharma-receives-nasdaq-notification-regarding-minimum-stockholders-equity-deficiency-302431912.html

SOURCE RedHill Biopharma Ltd.

Related Topics:
Continue Reading

Technology

APPOINTMENT OF CHAIRMAN OF THE AUDIT COMMITTEE

Published

38 minutes ago

on

November 13, 2026

By

JOHANNESBURG, Nov. 13, 2026 /PRNewswire/ — In compliance with para 6.71 of the JSE Listings Requirements and para 6.42 of the JSE Debt and Specialist Securities Listings Requirements, Sasol is pleased to announce the appointment of Mr Stanley Subramoney as the Chairman of the Audit Committee and Sasol’s financial expert with effect from 14 November 2026.

Mr Subramoney has been an independent non-executive director of Sasol Limited since 2021 and is a member of the Audit and Remuneration Committees. He is a chartered accountant with extensive experience in accounting, auditing and international business. During a 27-year career with PwC, he served as an audit and advisory partner and Deputy Chief Executive Officer of PwC Southern Africa. He gained significant international exposure through complex assignments and global organisational roles. He is currently Chief Executive Officer of Menston Holdings, a diversified investment company. He serves as an independent non-executive director of Nedbank Group, where he formerly chaired the Group Audit and Credit Committees.

The Chairman of the Sasol Board, Ms Muriel Dube, said: “Stanley has been a valued member of the Sasol Board and Audit Committee since 2021. His extensive accounting and audit expertise, together with his deep knowledge of Sasol gained during his tenure on the Board, position him well to lead the Audit Committee. The Board is confident that he will provide strong leadership to the Committee and continue to make a valuable contribution to Sasol.”

For further information, please contact:
Sasol Investor Relations,
Tiffany Sydow, VP Investor Relations
Telephone: +27 (0) 71 673 1929
investor.relations@sasol.com

 

View original content:https://www.prnewswire.com/news-releases/appointment-of-chairman-of-the-audit-committee-302938758.html

SOURCE Sasol Limited

Continue Reading

Technology

CCTV4: The special coverage APEC: Shenzhen Engagement will air

Published

38 minutes ago

on

November 13, 2026

By

BEIJING, Nov. 13, 2026 /PRNewswire/ — The 2026 APEC Summit will be held in Shenzhen, Guangdong Province, on November 18–19, attracting global attention. China Media Group’s Chinese Global Program Center has set up a front-line studio in Shenzhen. From November 13 to 19, China News will launch the special coverage APEC: Shenzhen Engagement in its flagship noon and evening slots. Adopting an international perspective and centered on the theme of “Building an Asia-Pacific Community for Common Prosperity”, the special coverage will present a comprehensive and multi-dimensional picture of the APEC Summit in Shenzhen through a rich array of reporting formats, including live broadcasts, studio discussions, high-profile interviews, and integrated-media live streams.

Guests from the China (Shenzhen) Development Institute and other institutions will be invited to the studio to discuss new models of global governance under the APEC cooperation framework amid key summit topics.

APEC Face to Face, a high-end interview segment, will feature exclusive conversations with attending dignitaries, senior officials of APEC economies, industry leaders, business figures, heads of multinational corporations and authoritative think tank experts. It combines dedicated in-depth interviews with on-the-spot interviews to capture hot topics of Asia-Pacific cooperation.

The integrated-media program Shenzhen’s New Landmarks uses six core landmark clusters across Shenzhen as its narrative thread. It integrates mobile live streaming, immersive exploration, feature videos and in-depth interviews to offer a panoramic view of Shenzhen’s development achievements and practical experience as a pioneer of China’s reform and opening up and a core engine of the Guangdong-Hong Kong-Macao Greater Bay Area.

The special coverage APEC: Shenzhen Engagement will air on China Media Group’s CCTV-4 (Chinese International Channel) at 12:00 and 18:00 from November 13 to 19. Stay tuned!

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/cctv4-the-special-coverage-apec-shenzhen-engagement-will-air-302938759.html

SOURCE CCTV4

Continue Reading

Technology

Bracco and Avicenna.AI Announce FDA Clearance for UPTUNITY™ | Aneurysm, a New AI-Enabled Software for Brain Aneurysm Detection and Assessment

Published

39 minutes ago

on

November 13, 2026

By

Developed in collaboration with Avicenna.AI, the newly FDA-cleared technology introduces UPTUNITY™, Bracco’s new portfolio of AI-enabled clinical decision support solutions.

MILAN, Nov. 13, 2026 /PRNewswire/ — Bracco and Avicenna.AI today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of UPTUNITY™ | Aneurysm, the first offering within the new UPTUNITY™ portfolio and a result of Bracco’s collaboration with Avicenna.AI. Designed to support medical specialists in detecting and assessing brain aneurysms on cerebral arteries computed tomography angiography (CTA) images, UPTUNITY | Aneurysm integrates AI assistance into the radiologist’s reading workflow.

UPTUNITY reinforces Bracco’s Digital Health strategy by expanding the company’s capabilities into interpretive AI. The portfolio provides clinical decision support capabilities for specific needs in image interpretation. It complements Bracco’s existing AI offerings, including AiMIFY®, developed with Subtle Medical, which applies AI to amplify existing contrast enhancement in brain MRI for improved lesion visualization.1 With UPTUNITY, Bracco continues to invest in Digital Health technologies that extend its support for radiologists across the imaging continuum and advance innovation beyond contrast agents.

“A small incidental aneurysm on a head CTA can easily be overlooked when the worklist keeps growing,” said Cosimo DePinto, Executive Vice President, Marketing & Commercial Operations, Bracco Americas. “UPTUNITY | Aneurysm works inside the reading environment radiologists already know and helps find the aneurysm hiding in the CT scan. The clinical decision stays where it belongs: with the radiologist.”

An estimated one in 50 U.S. adults has an unruptured brain aneurysm, a condition that is often asymptomatic.2 Aneurysms can be difficult to detect on cerebral arteries CTA and may be discovered incidentally during imaging performed to evaluate other clinical concerns.3,4 For known aneurysms, consistent follow-up and assessment of changes in growth are important to ongoing clinical evaluation.4

UPTUNITY | Aneurysm spans brain aneurysm detection and ongoing follow-up across the radiologist’s workflow. For detection, the computer-assisted detection (CADe) and diagnosis (CADx) software is intended for use as a concurrent reading aid by appropriately trained medical specialists. It identifies suspected saccular brain aneurysms greater than 3 mm on head CTA images and provides information about their presence, location and size for assessment and characterization. For known aneurysms, the follow-up functionality (MIMPS) provides quantitative measurements and comparison between examinations to assess changes over time. The integrated workflow extends from initial identification through longitudinal follow-up.

The software provides information for use alongside review of the CTA images, while maintaining physician control over clinical decision-making. It is not intended to replace a full patient evaluation or a qualified physician’s review and should not be solely relied upon to make or confirm a diagnosis.5,6

“For a patient with an unruptured aneurysm, the follow-up scan always brings the same question: has it changed?” said Fabio Tedoldi, PhD, Head of Global Research & Development, Bracco Imaging. “UPTUNITY | Aneurysm supports physicians from first detection through subsequent monitoring, with comparable readings at every exam. Precision, to us, means not only finding, but following up.”

Bracco and Avicenna.AI announced their strategic partnership in March 2026 to advance AI applications in contrast-enhanced computed tomography. The companies are now preparing for the commercial introduction of UPTUNITY | Aneurysm in the United States. Avicenna.AI will lead promotion and commercial distribution of the solution.

“Contrast agents were created to make the invisible visible. A brain aneurysm is exactly that kind of hidden finding: silent, often discovered by chance, then followed millimeter by millimeter for years. Bracco has spent decades lighting up the vessels. But an image only helps if what it shows is seen. Avicenna.AI brings AI assistance to those images, helping radiologists detect an aneurysm >3 mm and track how it changes over time,” said Cyril Di Grandi, CEO and co-founder, Avicenna.AI. “UPTUNITY | Aneurysm combines these two strengths, turning a head CTA into a story the radiologist can follow, from the first finding through every follow-up. Neither of us could have done this alone, and that is the point of this partnership.”

UPTUNITY | Aneurysm will be showcased at the Radiological Society of North America (RSNA) 2026 Annual Meeting, taking place November 29–December 3 in Chicago. To learn more about Bracco’s presence at RSNA 2026, including UPTUNITY | Aneurysm and the company’s vision for artificial intelligence, visit www.bracco.com/RSNA.

UPTUNITY | Aneurysm has received 510(k) clearance from the U.S. Food and Drug Administration under K262062 and K262147. UPTUNITY™ | Aneurysm Detection and UPTUNITY™ | Aneurysm Management are the commercial names for CINA-Aneurysm (K262062) and CINA-Aneurysm+ (K262147), respectively. For complete operating instructions, warnings, precautions and other important safety information, refer to the instructions for use.

About Bracco
Bracco Group, founded in 1927, is a global leader in diagnostic imaging committed to advancing healthcare and improving people’s lives by shaping the future of prevention and precision medicine. The company operates in the healthcare sector in more than 100 countries, with a workforce of over 4,000 employees and consolidated annual revenues of approximately €2 billion, with a global footprint.

With a strong commitment to innovation, investing around 9% of its reference turnover in research and development, Bracco develops and provides a broad portfolio of pharmaceutical products for diagnostic imaging, including contrast agents for X-ray, computed tomography and magnetic resonance imaging, as well as microbubbles for contrast-enhanced ultrasound and molecular imaging agents such as radioactive tracers and novel positron emission tomography imaging agents, alongside artificial intelligence-based solutions. It is also a global market leader in advanced contrast management technologies for cardiovascular angiography and radiology imaging. Discover more at www.bracco.com.

About Avicenna.AI
Founded in 2018, Avicenna.AI specializes in the development of artificial intelligence solutions dedicated to emergency and incidental medical imaging, using deep learning techniques to identify, detect and quantify critical pathologies from CT images. Co-founded by Cyril Di Grandi, co-founder of Olea Medical, and Dr. Peter Chang, American radiologist and AI expert, Avicenna.AI’s mission is to support radiologists’ diagnosis, ensure faster and more reliable detection of serious pathologies, and improve the quality of patient care through its AI tools for radiology. For more information, follow us on LinkedIn and visit our website: www.avicenna.ai

Media Contacts:

Bracco Press Contact
Alessandra Vulpiani
Bracco Imaging, Senior Marketing Communication Manager
Alessandra.Vulpiani@bracco.com

Avicenna.AI Press Contact
Stéphanie Bellavia
Avicenna.AI, Marketing Manager
stephanie.bellavia@avicenna.ai

1Venkata SP, Arnold TC, Serra SC, et al. Deep-Learning Based Contrast Boosting: A Multi-Center Multi-Reader Study on Clinical Performance With Standard Contrast Enhanced Brain MRI. J Magn Reson Imaging. 2026:1-15. doi:10.1002/jmri.70460.
2Brain Aneurysm Foundation. Brain Aneurysm Statistics and Facts. Available at: https://www.bafound.org/statistics-and-facts/. Accessed October 28, 2026.
3Biddle G, Assadsangabi R, Broadhead K, Hacein-Bey L, Ivanovic V. Diagnostic Errors in Cerebrovascular Pathology: Retrospective Analysis of a Neuroradiology Database at a Large Tertiary Academic Medical Center. AJNR Am J Neuroradiol. 2022;43(9):1271-1278. doi:10.3174/ajnr.A7596
4Thompson BG, Brown RD Jr, Amin-Hanjani S, et al. Guidelines for the Management of Patients With Unruptured Intracranial Aneurysms: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015;46(8):2368-2400.
5U.S. Food and Drug Administration. 510(k) Summary K262062, CINA-Aneurysm.
6U.S. Food and Drug Administration. 510(k) Summary K262147, CINA-Aneurysm+.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/bracco-and-avicennaai-announce-fda-clearance-for-uptunity–aneurysm-a-new-ai-enabled-software-for-brain-aneurysm-detection-and-assessment-302938510.html

Continue Reading

Trending